Prescriptions
Complexity has outpaced buyers’ ability to self‑diagnose
Feature checklists once won deals. Not anymore. Buying groups are bigger, cross‑functional, and risk‑sensitive: Forrester reports ~13 stakeholders per purchase, 89% of decisions span departments, and 86% of purchases stall—a perfect recipe for decision fatigue when sellers throw more features at the room. At the same time, buyers navigate about ten interaction channels and more than half will switch suppliers if the experience across those channels is clumsy. Clarity that travels cleanly across email threads, internal docs, and steering meetings matters more than another capability slide. [my.idc.com] [learn.g2.com]
Translation: buyers don’t want catalogs. They want prescriptions—diagnosis‑led, rationale‑rich recommendations that reduce risk and align stakeholders.
Feature‑led selling breeds confusion, not confidence
If your pipeline includes “one more demo” and “send us a comparison,” you’re seeing the cost of feature sprawl. In software categories, late‑stage hurdles are real: the CFO frequently holds final decision power (79%) and Legal slows or blocks 61% of purchases. Feature talk without a decision path dies in finance and legal review. Meanwhile, buyers are ~70% through their journey before speaking with sales and 81% already have a preferred vendor—so merely adding information rarely changes the outcome. A crisp prescription can. [storyproc.com]
Buyers aren’t comparing features, they’re comparing clarity
Feature pitches shift cognitive burden to the committee. They now must:
Map features to real problems.
Align functions on what matters.
Predict operational impact and risk.
Build a defendable business case for CFO/Legal.
Prescription selling removes that burden. It answers, “What should we do, why, and how fast will it pay back?” in language that survives the ~10‑channel journey inside the account. [learn.g2.com]
Why features fail: parity across vendors, endless interpretation, and longer evaluation cycles. Why prescriptions win: reduced complexity, higher trust, stronger champions, and faster convergence on a decision.
Prescription is leadership, not pressure
Teams don’t resist direction; they resist uneared direction. Prescriptions land when three conditions are met:
Clear diagnosis (buyers feel understood).
Goal alignment (the recommendation advances their KPIs, not your quota).
Autonomy preserved (conditional language keeps the choice theirs).
This matches how late‑stage committees decide under scrutiny from CFO and Legal with fast‑ROI expectations (57% of buyers expect ROI ≤ 3 months).
A 7‑step model: replace feature selling with prescription selling
1) Diagnose before you prescribe
“From slow approvals and inconsistent data to growth pressures, your constraint isn’t core functionality; it’s fragmented workflow.” Diagnosis earns authority—and gives committees a single problem statement to rally around. [my.idc.com]
2) Link diagnosis to an explicit objective
“Priority: cut cycle time without adding headcount.” Tying to KPIs primes CFO discussions and legal risk framing.
3) Prescribe the path—not the feature
“Standardize approvals with automated routing and pre‑approved criteria.” No catalog, just direction that travels through ~10 channels cleanly. [learn.g2.com]
4) Explain the ‘why this works’ rationale
“This removes cross‑team friction, reduces rework, and exposes bottlenecks—exactly where delays originate.” Rationale is the antidote to “pushy.” [my.idc.com]
5) Reveal the risk of alternatives
“An incremental tweak preserves bottlenecks and prolongs friction.” Present trade‑offs the way finance/legal will—neutral, risk‑aware.
6) Anchor to measurable outcomes
“Recover 8–12 hours/week and pull approvals in by 2–3 days.” Pair time gains with the toggle‑tax reality—knowledge workers lose 32 workdays/year to app‑switching—to keep estimates credible. [business.l…nkedin.com]
7) Make it repeatable for champions
“One sentence they can paste: Because delays come from manual rework and cross‑team friction, we should adopt a unified automation workflow to cut cycle time and workload.” Champions win internal meetings with copy‑ready clarity.
Why it works: prescriptions eliminate the buyer’s hidden burden
Decision overload: a recommended path reduces cognitive load across ~13 stakeholders. [my.idc.com]
Internal misalignment: a shared diagnosis and rationale curb circular debates over features. [learn.g2.com]
Risk sensitivity: prescriptions frame value and risk in the language CFO/Legal use, with payback expectations that match the market.
Features create possibilities. Prescriptions create decisions.
Implications for sales teams
Shorter cycles: committees align faster when you give them a path, not a menu. [learn.g2.com]
Higher win rates: prescriptions neutralize parity and comparison grids. [storyproc.com]
Better forecasts: clear, rationale‑backed decisions beat “maybe” signals. [my.idc.com]
Stronger champions: repeatable, CFO‑ready narratives survive finance/legal.
Actionable takeaways
Swap feature demos for diagnostic conversations anchored to KPIs. [my.idc.com]
Use conditional phrasing (“If X is the priority, the best path is…”) to preserve autonomy. [learn.g2.com]
Attach a three‑point rationale and a measurable outcome (with the toggle‑tax as a credible time baseline). [business.l…nkedin.com]
Provide a concise internal message champions can paste into the approval deck. [learn.g2.com]
In a crowded market where products look alike, the seller who prescribes—with diagnosis, rationale, and measurable outcomes—wins. Features inform. Prescriptions decide.
